Cotadutide vs Mazdutide
Head-to-head comparison of Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cotadutide | Mazdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | ~4,700 Da | ~5,000 Da |
| Half-Life | Approximately 24 hours | 5-7 days |
| Amino Acids | 37 | 37 |
| Typical Dose | 0.3-3 mg daily in clinical studies | 1-6 mg weekly in obesity trials |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 18 | 28 |
| Research Status | Clinical | Clinical |
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.